KYTX
NASDAQKyverna Therapeutics Inc.
$9.05+0.13 (+1.40%)
News25/Ratings9
Price$9.05+0.37 (+4.20%)
01:30 PM07:45 PM
News · 26 weeks58-18%
2025-11-022026-04-26
Mix3590d
- SEC Filings15(43%)
- Insider9(26%)
- Other6(17%)
- Earnings3(9%)
- Leadership2(6%)
Latest news
25 items- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingSingle-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive prima
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial Totality of efficacy and safety data reinforces miv-cel's differentiated and potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive longer-term follow-up data from the Phase 2 por
- SECSEC Form DEFA14A filed by Kyverna Therapeutics Inc.DEFA14A - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECSEC Form DEF 14A filed by Kyverna Therapeutics Inc.DEF 14A - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, April 22, 2026 at 7:00 a.m. ET to discuss the primary analysis from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome, along with longer-term follow-up data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis (gMG). These data will be shared as oral presentations at the American Academy of Neurology (AAN) Annual Meeting, held April 18-22,
- SECSEC Form 144 filed by Kyverna Therapeutics Inc.144 - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- SECSEC Form EFFECT filed by Kyverna Therapeutics Inc.EFFECT - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECSEC Form 424B5 filed by Kyverna Therapeutics Inc.424B5 - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECSEC Form 144 filed by Kyverna Therapeutics Inc.144 - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- SECSEC Form S-8 filed by Kyverna Therapeutics Inc.S-8 - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECSEC Form S-3 filed by Kyverna Therapeutics Inc.S-3 - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECSEC Form 10-K filed by Kyverna Therapeutics Inc.10-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsAdvancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple sclerosis data underscore valuable pipeline-in-a-product opportunity with miv-cel Cash and cash equivalents of $279 million provide expected runway into 2028, funding SPS BLA filing, commercial launch, and Phase 3 gMG trial EMERYVILLE, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell th
- INSIDERChief Financial Officer Grasso Marc was granted 10,000 shares (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERChief Executive Officer Biddle Warner Weston was granted 58,000 shares (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDEROfficer Gehchan Naji was granted 18,000 shares (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- PRKyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced multiple abstracts selected for presentation at the American Academy of Neurology (AAN) Annual Meeting, taking place from April 18-22, 2026, in Chicago, IL. "Our presence at AAN marks an important milestone for Kyverna as we build upon miv-cel's potential to re
- INSIDERSEC Form 3 filed by new insider Miller Andrew Craig3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Miller Andrew Craig was granted 11,006 shares (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- PRKyverna Therapeutics to Participate in Upcoming March Investor ConferencesEMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced that company management will participate in the following upcoming conferences: Leerink Partners 2026 Global Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Monday, March 9th, 2026Time: 11:20 a.m. ET 2026 Jefferies Biotech on the Beach SummitFormat: Investor meetingsDate: Tuesday, March 10th, 2026 A live webcast of the Leerink fireside chat may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast
- INSIDERSEC Form 3 filed by new insider Emany Sravan Kumar3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)